OBJECTIVE: To prospectively measure the link between depressive symptoms and functional outcomes in the long-term treatment of people with schizophrenia. METHODS: Data were drawn from a large, multi-site, 3-year, prospective, naturalistic, observational study, in which subjects with schizophrenia were assessed at enrollment and at 12-month intervals thereafter. Individuals who were "Depressed" (defined as a total score > or =16 on the Montgomery-Asberg Depression Rating Scale) at enrollment were compared to those "Non-depressed" on functional outcomes, using self-report measures, clinicians' ratings, and information from medical records. Statistical analyses included Generalized Estimation Equation and mixed regression analyses adjusted for individual characteristics. Longitudinal group comparisons across the 3-year study were augmented with a cross-sectional group comparison at enrollment. RESULTS: At enrollment, 39.4% (877/2228) of the participants were deemed Depressed. Across the 3-year study, the depressed cohort was significantly more likely than the Non-depressed to use relapse-related mental health services (emergency psychiatric services, sessions with psychiatrists); to be a safety concern (violent, arrested, victimized, suicidal); to have greater substance-related problems; and to report poorer life satisfaction, quality of life, mental functioning, family relationships, and medication adherence. Furthermore, changes in depressed status were associated with changes in functional outcomes. CONCLUSIONS: People with schizophrenia and concurrent depressive symptoms have poorer long-term functional outcomes compared to the Non-depressed. Their poorer quality of life, greater use of mental health services, and higher risk of involvement with law enforcement agencies underscore a need for special treatment interventions. Treatment of the non-psychotic dimensions of schizophrenia is a critical part of recovery.
OBJECTIVE: To prospectively measure the link between depressive symptoms and functional outcomes in the long-term treatment of people with schizophrenia. METHODS: Data were drawn from a large, multi-site, 3-year, prospective, naturalistic, observational study, in which subjects with schizophrenia were assessed at enrollment and at 12-month intervals thereafter. Individuals who were "Depressed" (defined as a total score > or =16 on the Montgomery-Asberg Depression Rating Scale) at enrollment were compared to those "Non-depressed" on functional outcomes, using self-report measures, clinicians' ratings, and information from medical records. Statistical analyses included Generalized Estimation Equation and mixed regression analyses adjusted for individual characteristics. Longitudinal group comparisons across the 3-year study were augmented with a cross-sectional group comparison at enrollment. RESULTS: At enrollment, 39.4% (877/2228) of the participants were deemed Depressed. Across the 3-year study, the depressed cohort was significantly more likely than the Non-depressed to use relapse-related mental health services (emergency psychiatric services, sessions with psychiatrists); to be a safety concern (violent, arrested, victimized, suicidal); to have greater substance-related problems; and to report poorer life satisfaction, quality of life, mental functioning, family relationships, and medication adherence. Furthermore, changes in depressed status were associated with changes in functional outcomes. CONCLUSIONS:People with schizophrenia and concurrent depressive symptoms have poorer long-term functional outcomes compared to the Non-depressed. Their poorer quality of life, greater use of mental health services, and higher risk of involvement with law enforcement agencies underscore a need for special treatment interventions. Treatment of the non-psychotic dimensions of schizophrenia is a critical part of recovery.
Authors: Deanna L Kelly; Joo-Cheol Shim; Stephanie M Feldman; Yang Yu; Robert R Conley Journal: J Psychiatr Res Date: 2004 Sep-Oct Impact factor: 4.791
Authors: Anthony F Lehman; Ellen P Fischer; Leticia Postrado; Janine Delahanty; Bryan M Johnstone; Patricia A Russo; William H Crown Journal: Schizophr Bull Date: 2003 Impact factor: 9.306
Authors: Joshua Chiappelli; Laura M Rowland; S Andrea Wijtenburg; Florian Muellerklein; Malle Tagamets; Robert P McMahon; Frank Gaston; Peter Kochunov; L Elliot Hong Journal: Neuropsychopharmacology Date: 2015-02-27 Impact factor: 7.853
Authors: Brandee Feola; Kristan Armstrong; Neil D Woodward; Stephan Heckers; Jennifer Urbano Blackford Journal: Psychiatry Res Date: 2019-03-11 Impact factor: 3.222
Authors: Rachel Upthegrove; Paris Lalousis; Pavan Mallikarjun; Katharine Chisholm; Sian Lowri Griffiths; Mariam Iqbal; Mirabel Pelton; Renate Reniers; Alexandra Stainton; Marlene Rosen; Anne Ruef; Dominic B Dwyer; Marian Surman; Theresa Haidl; Nora Penzel; Lana Kambeitz-Llankovic; Alessandro Bertolino; Paolo Brambilla; Stefan Borgwardt; Joseph Kambeitz; Rebekka Lencer; Christos Pantelis; Stephan Ruhrmann; Frauke Schultze-Lutter; Raimo K R Salokangas; Eva Meisenzahl; Stephen J Wood; Nikolaos Koutsouleris Journal: Schizophr Bull Date: 2021-01-23 Impact factor: 9.306
Authors: Amy K Nuttall; Katharine N Thakkar; Xiaochen Luo; Kim T Mueser; Shirley M Glynn; Eric D Achtyes; John M Kane Journal: Psychiatry Res Date: 2019-04-16 Impact factor: 3.222
Authors: Brent T Mausbach; Raeanne C Moore; Taylor Davine; Veronica Cardenas; Christopher R Bowie; Jennifer Ho; Dilip V Jeste; Thomas L Patterson Journal: Psychiatry Res Date: 2012-09-29 Impact factor: 3.222